Monopar Therapeutics, Inc., a Chicago, IL-based biopharmaceutical company focused on developing innovative drug candidates to improve clinical outcomes in cancer patients, closed a $9.7m financing round.
Monopar also acquired GPX-150, a novel non-cardiotoxic anthracycline from privately held Gem Pharmaceuticals. GPX-150 has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the potential for irreversible damage to the heart.
Led by Dr. Chandler Robinson, CEO, and Dr. Andrew Mazar, CSO, Monopar is a biopharmaceutical company focused on building a drug development pipeline through the licensing and acquisition of oncology therapeutics at the late preclinical through advanced clinical development stage that have demonstrated good antitumor efficacy and safety when used in combination.
The company recently announced an exclusive worldwide license to develop, register, commercialize and manufacture Validive®, a Phase III-ready prevention of and treatment for radiation induced severe oral mucositis (SOM) in head and neck cancer. It currently has three compounds in development: Phase III-ready Validive® (clonidine mucobuccal tablet; clonidine MBT); Phase II-stage GPX-150; and near-to-the-clinic MNPR-101, a humanized monoclonal antibody that targets the urokinase plasminogen activator receptor (uPAR).